PIK3CA and breast cancer: To assess the effect of PAM inhibitors on protein synthesis, four BC cell lines with different PIK3CA and PTEN mutational status were treated with increasing concentrations of gedatolisib, alpelisib, capivasertib, or everolimus for approximately 20 h and analyzed by flow cytometry for protein synthesis (assessed by OPP incorporation) as well as for p4EBP1 and pRPS6 (used as a marker of S6Ks activity).